ICMJE DISCLOSURE FORM

Date: 09.03.2021	
Your Name: Attila Kollàr	
Manuscript Title: Ripretinib – a new star in the firmament	
Manuscript number (if known): GIST-21-3	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months		
_		None			
3	Royalties or licenses	None			
4	Consulting fees	None			

5	Payment or honoraria for lectures, presentations,	Bayer	Honoraria for lectures
		Lilly	Honoraria for lectures
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
-			7 1 .
7	Support for attending meetings and/or travel	Ipsen, Pharmamar, Amgen	Travel support
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	Roche	Participation on an Advisory Board
	Safety Monitoring Board or Advisory Board	Lilly	Participation on an Advisory Board
		Lilly	Tarticipation on an Advisory Board
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	1 Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	TVOTE	
	aa. meereses		

Please summarize the above conflict of interest in the following box:

Honoraria for lectures: Bayer, Eli Lilly
Travel Support: Ipsen, Pharmamar, Amgen
Participation on an Advisory Board : Roche, Lilly

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.